Line up the metabolic research peptides in most catalogs and a pattern emerges: semaglutide, tirzepatide, retatrutide. They form a clear progression, each engaging more incretin receptors than the last. Then there is cagrilintide, which does not fit the pattern at all, because it is not an incretin peptide. Understanding why it sits apart is the fastest way to understand what the whole metabolic category is actually made of.
What “incretin” means
The incretins are a class of gut hormones, most importantly GLP-1 and GIP, that the body releases in response to food. Research peptides in the metabolic series are mostly incretin mimetics: semaglutide is a GLP-1 analogue, tirzepatide engages both GLP-1 and GIP receptors, and retatrutide adds a third, the glucagon receptor. Reading that progression by receptor count is the cleanest way to keep them straight, and our retatrutide overview and tirzepatide overview trace it out.
Where cagrilintide comes from instead
Cagrilintide is an analogue of amylin, not of any incretin. Amylin is a hormone co-secreted with insulin from the same pancreatic cells, and it operates through an entirely separate receptor system from the incretins. This is the whole point: cagrilintide is studied because it acts on a pathway the GLP-1 and GIP compounds do not touch. It is the amylin arm of metabolic research, sitting alongside the incretin arm rather than within it.
Why the distinction is the interesting part
The reason cagrilintide draws research attention is precisely that it is mechanistically independent from the incretins. Two compounds acting on the same receptor are, to a first approximation, competing to do the same job. Two compounds acting on separate pathways can be studied in combination, each contributing something the other cannot. This is why cagrilintide appears in the literature alongside GLP-1 analogues rather than as a replacement for them: amylin plus incretin is two levers, not one lever pulled twice. In a catalog otherwise organized by how many incretin receptors a peptide hits, cagrilintide is the compound that changes the axis entirely.
What it shares with the rest
For all its mechanistic difference, cagrilintide is handled and verified exactly like its incretin neighbors. It is a lyophilized peptide, reconstituted the same way, stored the same way. Identity is confirmed by mass spectrometry and purity by high-performance liquid chromatography. If anything, the mechanistic distinctiveness makes identity testing more interesting rather than less: confirming the mass confirms you have the amylin analogue and not one of the incretin compounds it is often studied beside. Our guide to reading a certificate of analysis covers the fields that matter.
The bottom line
The metabolic research series reads as an incretin progression: one receptor, two, three, from semaglutide to tirzepatide to retatrutide. Cagrilintide is the outlier, an amylin analogue working through a separate pathway, and that is exactly why it is studied alongside the incretin compounds rather than among them. When a lineup is organized by incretin receptor count, the most informative member is the one that is not an incretin at all.
Heartland Bio Labs supplies these peptides strictly for laboratory research use. Nothing in this article is guidance for human or veterinary use of any compound.
Research compounds in this article
For research use only. Not for human consumption. Every product ships with a published certificate of analysis.